Researchers use salmonella to deliver oral DNA vaccines; Inviragen and the International Vaccine Institute strengthen partnership;

 @AlisonBFierce: The percentage of drug-resistant malaria cases is on the rise in Southeast Asia, a cause for concern among experts. More | Follow @AlisonBFierce

> Researchers use self-destructing salmonella to deliver oral DNA vaccines. Story

> Astellas Pharma launched in Japan the Quattrovac subcutaneous injection syringe, which delivers a combined vaccine for the prevention of pertussis, diphtheria, tetanus and poliomyelitis. Story

> The Sabin Vaccine Institute started Part II of its Phase I clinical trial of its Na-GST-1 vaccine candidate, a human hookworm vaccine. Release

> Immatics' renal cancer vaccine IMA901 completed Phase III patient recruitment and was granted U.S. orphan drug designation by the FDA. Release

And Finally... Inviragen and the International Vaccine Institute announced a collaboration to assess the total health burden of dengue cases in Colombia and Thailand. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.